Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Hepion Pharmaceuticals Inc
NASDAQ HEPA
Data sourced from
and
and
Hepion Pharmaceuticals Inc Return on Tangible Equity (ROTE) 3 year CAGR for the quarter ending December 31, 2022: -5.02%
Hepion Pharmaceuticals Inc Return on Tangible Equity (ROTE) 3 year CAGR is -5.02% for the quarter ending December 31, 2022. Return on tangible equity measures the profitability of a company relative to its tangible equity, which is shareholders' equity minus goodwill and intangible assets. It is calculated by dividing the net income by the tangible equity. This ratio indicates the return generated for each unit of tangible equity invested by the shareholders. A higher return on tangible equity suggests better profitability and value creation for the shareholders' tangible investment. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
Hepion Pharmaceuticals Inc Return on Tangible Equity (ROTE) for the quarter ending March 31, 2022 was -11.90%, a -121.04% change year over year.
-
Hepion Pharmaceuticals Inc Return on Tangible Equity (ROTE) for the quarter ending March 31, 2021 was -5.38%, a 68.39% change year over year.
-
Hepion Pharmaceuticals Inc Return on Tangible Equity (ROTE) for the quarter ending March 31, 2020 was -17.03%, a -137.91% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: HEPA
| CEO | Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D. |
| IPO Date | Feb. 11, 2014 |
| Location | United States |
| Headquarters | 399 Thornall Street, Edison, NJ, United States, 08837 |
| Employees | 22 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Key trends
Similar companies
AVROBIO Inc
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email